MIR663A is a known NSCLC tumor suppressor that acts through a variety of downstream targets, including TGFβ, p53, p21, and JunD [45], [46], [47], and its predicted targets include ACSL3, TGFB1, and HOXC10. Here, TP53 is linked to neoplasm.